Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2005; 93(03): 620-622
DOI: 10.1055/s-0037-1616563
DOI: 10.1055/s-0037-1616563
Letters to the Editor
Different effects of low-dose transdermal and oral oestrogen therapy on procarboxypeptidase U, an inhibitor of fibrinolysis, in healthy postmenopausal women: A randomised, placebo-controlled study
Grant support: This work was supported by research grants from the Netherlands Heart Foundation (grant 95.201), Biocare Foundation (grant 96.312), and Schering AG (Berlin, Germany, grant 96.083). J. R. Leurs was a research assistant of the Fund for Scientific Research Flanders (FWO-Vlaanderen).
Further Information
Publication History
Received
26 July 2004
Accepted after resubmission 28 December 2004
Publication Date:
14 December 2017 (online)
-
References
- 1 Lowe GDO, Upton MN, Rumley A. et al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein. Thromb Haemost 2001; 86: 550-6.
- 2 Post MS, Thomassen MCLGD, van der Mooren MJ. et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003; 23: 1116-21.
- 3 Post MS, van der Mooren MJ, van Baal WM. et al. Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in postmenopausal women: a randomized placebo-controlled study. Am J Obstet Gynecol 2003; 189: 1221-7.
- 4 Van Baal WM, Emeis JJ, van der Mooren MJ. et al. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo- controlled 12-week study. Thromb Haemost 2000; 83: 29-34.
- 5 Post MS, Hendriks DF, van der Mooren MJ. et al. Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized placebocontrolled 12-week study in early postmenopausal women. J Intern Med 2002; 251: 245-51.
- 6 Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-32.
- 7 Hulley S, Grady D, Bush T. et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.
- 8 Manson JE, Hsia J, Johnson KC. et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523-34.
- 9 Hendriks DF, Scharpe SS, van Sande M. et al. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27: 277-85.
- 10 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
- 11 Wang W, Boffa MB, Bajzar L. et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
- 12 Leurs J, Wissing BM, Nerme V. et al. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma. Thromb Haemost 2003; 89: 264-71.
- 13 Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
- 14 Silveira A, Schatteman KA, Goossens FJ. et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-8.
- 15 Post MS, van der Mooren MJ, Stehouwer CDA. et al. Effects of transdermal and oral oestrogen replacement therapy on C-reactive protein levels in postmenopausal women: a randomised, placebocontrolled study. Thromb Haemost 2002; 88: 605-10.
- 16 Smolders RGV, van der Mooren MJ, Teerlink T. et al. A randomized placebo-controlled study of the effect of transdermal vs. oral estradiol with or without gestodene on homocysteine levels. Fertil Steril 2003; 79: 261-7.
- 17 Vogelvang TE, van der Mooren MJ, Kamp O. et al. Effects of oral and transdermal low-dose estrogen therapy on echocardiographic parameters of cardiac function. Fertil Steril 2003; 80: 546-53.
- 18 Hemelaar M, van der Mooren MJ, Mijatovic V. et al. Oral, more than transdermal, estrogen replacement therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study. Menopause 2003; 10: 550-8.
- 19 Schatteman KA, Goossens FJ, Leurs JR. et al. Fast homogeneous assay for plasma procarboxypeptidase U. Clin Chem Lab Med 2001; 39: 806-10.
- 20 Vogelvang TE, Leurs JR, van der Mooren MJ. et al. Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women. Menopause 2004; 11: 110-5.
- 21 Bladbjerg EM, Madsen JS, Kristensen SR. et al. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. J Thromb Haemost 2003; 1: 1208-14.
- 22 Leurs J, Nerme V, Sim Y. et al. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism. J Thromb Haemost 2004; 2: 416-23.
- 23 Clarke SC, Kelleher J, Lloyd-Jones H. et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study. Br J Obstet Gynaecol 2002; 109: 1056-62.
- 24 Anderson GL, Limacher M, Assaf AR. et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12.
- 25 Juhan-Vague I, Morange PE, Aubert H. et al. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002; 22: 867-73.